A Polish research confirmed that folks with type 1 diabetes on insulin pump remedy who used an computerized bolus calculator that recognised voice descriptions of meals had improved postprandial blood sugars.
The VoiceDiab system contains an Android-system smartphone with an app that communicates with three servers. These servers mix to create computerized speech recognition, textual content evaluation and insulin dosage calculation.
The servers comply with an algorithm that transforms verbal descriptions of meal into textual content; analyses the descriptions to infer quantities of carbohydrate, protein and fats; then calculates the insulin dose required.
The algorithm takes benefit of the Polish system which mixes carbohydrate with counting of protein and fat to realize higher control of blood sugar ranges than carb counting alone. The WBT (wymienniki bialkowo-tluszczowe, which suggests protein-fat exchanges) system has been developed by one of many researchers, professor Ewa Pankowska.
“The primary reasons for the use of software applications in bolus calculation are technological opportunities and the reduction of errors in dose calculation by patients using bolus calculators,” explains Piotr Foltynski, PhD, of the Nalecz Institute of Biocybernetics and Biomedical Engineering on the Polish Academy of Sciences in Warsaw.
“Low numeracy is associated with poor diabetes control; therefore, the use of bolus advisors may bring benefits to the patients.”
In a research carried out between March 2015 and January 2016, 44 adults with type 1 diabetes handled with an insulin pump have been randomised to both use the VoiceDiab system or not. Then, after a 14-day break, they switched teams.
The VoiceDiab speech recognition group skilled higher post-meal blood sugar ranges in comparison with the non-support group, and no elevated incidences of hypoglycemia or hyperglycemia have been noticed.
“The VoiceDiab system allows improving postprandial glucose control without increasing the time of hyper or hypoglycemia, and therefore, it seems to be a promising tool for use by patients with diabetes treated with insulin,” concluded the authors.
The findings have been revealed in the Journal of Diabetes.
